Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 10, 2019
Reporting Period: Quarter ended March 31, 2019
Context: The filing announces the Company's financial results for the quarter ended March 31, 2019. The detailed results are contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided text serves as a cover document for the financial results and does not contain specific numerical data. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are located in the referenced Exhibit 99.1 (Press Release), which is not included in the input content.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the full text of the press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Guidance and Outlook: The filing text does not contain specific guidance or management commentary regarding future performance.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt. The document notes that the information is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for the forward-looking statements contained in the referenced exhibit.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the quarter ended March 31, 2019.
- Verify year-over-year comparisons and material changes in operating expenses or R&D spending.
- Confirm the Company's status as an "Emerging Growth Company" and its election not to use the extended transition period for new accounting standards.
- Check the Nasdaq Global Select Market listing status for Common Stock (Symbol: OCUL).